TABLE 47Measures of behavioural effect and mood in included studies: combination therapy

StudySubgroupOutcomeTypeAChEI + memantineAChEI + placebop-value
nMean (SD)nMean (SD)
Porsteinsson et al. (2008)150LOCF analysisNPI – 24 weeksMC2120.70 (12.01)a2090.40 (12.29)aNSb
C21212.9 (14.5)20912.6 (14.6)0.743b
OC populationNPI – 12 weeksMC1930.80 (10.77)a1890.30 (10.65)aNSb
NPI – 24 weeksMC1930.00 (11.81)a1890.00 (11.69)aNSb
NPI – 24 weeksC19312.3 (13.7)18911.9 (13.5)0.985b

C, continuous; MC, mean change; NS, not statistically significant.

a

Data estimated from figure.

b

ANCOVA (treatment group and centre as main effects; baseline score as covariate).

Data estimated from figure.

ANCOVA (treatment group and centre as main effects; baseline score as covariate).

From: 3, Assessment of clinical effectiveness

Cover of The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model
The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model.
Health Technology Assessment, No. 16.21.
Bond M, Rogers G, Peters J, et al.
Southampton (UK): NIHR Journals Library; 2012 Apr.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.